Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: The company's forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain's second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca's sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his "more constructive thesis" for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon's Savvas Neophytou remains more wary, pointing out that Soriot's predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca's longer-term prospects. "In our view, management is stepping onto thin ice with this same sort of guidance," Neophytou said, pointing out the previous management's failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb's share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts' revenue forecasts significantly, suggesting that a more realistic "adjusted consensus" for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company's thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body's immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients' lives significantly and generate tens of billions of dollars in annual sales.

Output: Drugmaker AstraZeneca forecasts faster return to growth.

Input: Consider Input: The FDA said it received 85 reports from patients who switched from Wellbutrin XL to Teva Pharmaceutical Industries Ltd and Impax Laboratories Inc's cheaper generic, including 78 who said they slipped back into depression. Other patients reported new or worsening side effects, including headaches, fatigue, anxiety and digestion issues. "The question is whether the reported lack of efficacy and/or new onset side effects in these patients who switched suggest a problem with the generic product ... or have some other explanation," the FDA said in a statement on its website. Agency scientists reviewed 300-milligram versions of the two drugs, which both use once-a-day formulations of the chemical bupropion, and found the data did not show that the problems stemmed from any differences between the two drugs. One factor that could account for the reported problems is the natural recurrence of depression, which can happen despite treatment, the FDA said. Half of the patients who went back on the name-brand drug said they improved, the agency said, adding that it would continue to monitor the issue. FDA officials received the reports during the first half of 2007. Teva and Impax's version of Wellbutrin was approved in 2006. Watson Pharmaceuticals Inc also makes a 300-mg XL version of bupropion, though it was not part of the FDA's review. GlaxoSmithKline makes other versions of Wellbutrin that face generic competition. Total sales of Wellbutrin slipped 37 percent last year in the face of generic competition, the company has reported. The drugmaker could not comment on the FDA's conclusion because it did not have access to the data used but is pleased the agency would continue its monitoring, GlaxoSmithKline spokeswoman Mary Anne Rhyne said. Teva spokeswoman Denise Bradley said the company would issue a statement later. Shares of GlaxoSmithKline rose 39 cents to $42.47 on the New York Stock Exchange. Teva rose 65 cents, or 1.4 percent, to $46.67 on Nasdaq.

Output: FDA says generic Wellbutrin OK despite reports.

Input: Consider Input: "The story does not mention costs of either drug, other than to describe the costs of ellaOne as ""three times the price of Plan B."" The story adequately quantifies the benefits of ellaOne by presenting both the number of pregnancies and the pregnancy rate in both groups. The story doesn't mention any potential harms of the drug, other than unwanted pregnancy. In the study 19% of women experienced headaches and one dizziness. Common side effects of the drug also include stomach pain and nausea, cramps, and vaginal bleeding. None of these were mentioned in the story. The story adequately describes the design of the current study. The story does not engage in disease-mongering. The story quotes two independent health officials who provide very valuable perspectives on the new findings. The story compares the new drug to the existing option, Levonorgestrel. The story clearly states that ellaOne is only available by prescription in Europe, whereas Levonorgestrel is available in many countries worldwide, including the US. The story accurately represents the novelty of ellaOne compared to Levonorgestrel. Because the story quotes independent researchers and health officials, the reader can assume the story does not rely on a press release as the sole source of information."
Output: New morning-after pill works for up to 5 days